Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.
Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.
复制标题
DOI：
10.1186/1477-5956-8-70
复制
发表时间：
2010-12-31
期刊：
影响因子：
2
通讯作者：
Tsubouchi H
中科院分区：
文献类型：
--
作者：
Uto H;Kanmura S;Takami Y;Tsubouchi H
肝细胞癌（HCC）是第五大常见癌症，晚期肝纤维化是 HCC 的主要危险因素。包括肝硬化和肝癌在内的肝纤维化主要由乙型或丙型肝炎病毒持续感染引起，全球约有5亿人感染乙型或丙型肝炎病毒。此外，近来患有非酒精性脂肪肝病(NAFLD)的患者数量有所增加，并且NAFLD可进展为肝硬化和HCC。这些慢性肝病是发病和死亡的主要原因，非侵入性生物标志物的识别对于早期诊断非常重要。定量和大规模蛋白质组学方法的最新进展可用于优化生物标志物的临床应用。 HCC 的早期诊断和肝纤维化或 NAFLD 阶段的评估也有助于更有效的治疗干预和改善预后。此外，蛋白质组学技术的进步不仅有助于发现临床上有用的生物标志物，而且还有助于通过使用体液（例如血清）、组织样本和培养细胞来阐明疾病发病机制的分子机制。在这篇综述中，我们报告了定量蛋白质组学的最新进展以及一些针对肝脏疾病的研究结果，包括 HCC、NAFLD、肝纤维化和乙型或丙型肝炎病毒感染。
Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C virus infection, with approximately 500 million people infected with hepatitis B or C virus worldwide. Furthermore, the number of patients with non-alcoholic fatty liver disease (NAFLD) has recently increased and NAFLD can progress to cirrhosis and HCC. These chronic liver diseases are major causes of morbidity and mortality, and the identification of non-invasive biomarkers is important for early diagnosis. Recent advancements in quantitative and large-scale proteomic methods could be used to optimize the clinical application of biomarkers. Early diagnosis of HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis. Furthermore, advancements of proteomic techniques contribute not only to the discovery of clinically useful biomarkers, but also in clarifying the molecular mechanisms of disease pathogenesis by using body fluids, such as serum, and tissue samples and cultured cells. In this review, we report recent advances in quantitative proteomics and several findings focused on liver diseases, including HCC, NAFLD, hepatic fibrosis and hepatitis B or C virus infections.
登录
查看更多内容
影响因子：
3.4
作者：
Feng, JT;Liu, YK;Tang, ZY
通讯作者：
Tang, ZY
影响因子：
2.5
作者：
Cheung, K. J.;Tilleman, K.;Van Vlierberghe, H.
通讯作者：
Van Vlierberghe, H.
影响因子：
4
作者：
He, Qing-Yu;Zhu, Rui;Chiu, Jen-Fu
通讯作者：
Chiu, Jen-Fu
影响因子：
7
作者：
Chen, GA;Gharib, TG;Beer, DG
通讯作者：
Beer, DG
影响因子：
3.8
作者：
Gray J;Chattopadhyay D;Beale GS;Patman GL;Miele L;King BP;Stewart S;Hudson M;Day CP;Manas DM;Reeves HL
通讯作者：
Reeves HL